The CEO of Tarsus shares an update on the launch of XDEMVY, and what the company is doing to reach more patients in the quarters ahead

blonca9
Sep 3, 2024
1 min read

Bobby Azamian describes how Tarsus has expanded its salesforce by 50%, and will be adding a DTC element to the launch and derive additional evidence for physicians. Plus, a pipeline update.

Recent Posts

See All

Checking in with MoonLake's CEO ahead of one of biotech's most closely watched trial readouts of the year - the phase 3 VELA program of sonelokimab in HS (due in Sept)

KalVista's CEO discusses today's FDA approval and commercial launch of Ekterly, the first oral therapy for treating hereditary angioedema (HAE) attacks

AI News: Singapore based Gero, a company focused on small molecules for aging conditions, launched ProtoBind-Diff, a model using amino acid sequences rather than structure models for discovery

The CEO of Tarsus shares an update on the launch of XDEMVY, and what the company is doing to reach more patients in the quarters ahead

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight